G. K. Rangan, D.A. Joyce. Regulation of tubular epithelial cell proliferation and cyclin D1 by NF-kB/Rel in proteinuric chronic renal diseases. ($35,000). Medical Research Foundation of WA. 2001
M-H Zheng, DA Joyce, Langdon W et al. Large Equipment Grant: BMG Polarstar Optima Microplate Fluorimeter/Luminometer ($82,045). University of WA Permanent Endowment for Medical Research. 2003
J. Xu, D.A. Joyce. Inhibition of RANKL-induced osteoclastogenesis through modulation of NF-кB signalling by PKC isoforms and parthenolide ($20,000). Arthritis Foundation of Western Australia. 2005
G. K. Rangan, D.A. Joyce, JH Steer. Regulation of tubular epithelial cell proliferation and cyclin D1 by NF-kB/Rel in proteinuric chronic renal diseases. ($10,000). Fremantle Hospital Medical Research Foundation. 2002
D.A. Joyce, J.H. Steer. Rac-ROS-NF-kB Pathways in Survival and Growth of Fibroblasts and Macrophages in Chronic Inflammatory Synovial Disease ($10,000). Sir Charles Gairdner Hospital Research Foundation. 2002
DA Joyce; PJ Henry. Macrophage uncoupling protein-2 regulation and expression in inflammatory joint disease and hyperoxic lung damage ($259,250). National Health & Medical Research Council. 2009 -2011
S Ching, C Newbound, DA Joyce, J Beilby. The development of improved pharmacogenomic reporting of thiopurine methyl transferase (TPMT) enzyme activity and genotypes. ($13,500). PathWest QEII Research Grant. 2009 -2010
S Schug, DA Joyce, JJ Inglis. Osteoarthritis pain: Mechanisms and mediators. The roles of NGF and IL-1 ($59,480). Australian and New Zealand College of Anaesthetists. Faculty of Pain Medicine. 2014- 2015.
D Purtill, D Pepperall, J Cooney, DA Joyce. Clinical and laboratory characterisation of endothelial toxicity in patients undergoing conditioning for allogeneic haematopoietic stem cell transplantation ($20,000). Cancer and Palliative Care Network, Health Dept of WA. 2015 -2016.
N Forrest, DA Joyce. Optimising antibiotic (piperacillin/ tazobactam) therapy in pleural infection and cystic fibrosis using a newly developed antibiotic assay ($46,005). North Metropolitan Health Service Research Advisory Council. 2016 -2017.
W. Lim, DA Joyce, G Wong, A Teixeira-Pinto, PL Thompson. Safety, tolerability and effect on inflammatory marker of colchicine in kidney transplant recipients ($37,017). Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee. 2017 -2018.
G. MacQuillan, DA Joyce, S O'Halloran, D White. Ethanol abstinence compliance optimisation using measurements of erythrocyte phosphatidylethanol ($27,047). Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee. 2019 -2020.
Prof. David Joyce heads Clinical Pharmacology research in the Pharmacology unit at UWA, with specific research interests in clinical pharmacokinetics in the context of therapeutic drug monitoring and the pharmacological control of macrophage function in inflammatory and neoplastic diseases.
Prof. Joyce is director of the Clinical Pharmacology & Toxicology laboratory at PathWest Laboratory Medicine, practices clinically in the areas of general internal medicine and clinical pharmacology at Sir Charles Gairdner Hospital and consults in forensic toxicology.
Prof. Joyce also coordinates undergraduate medical teaching in pharmacology and therapeutics at UWA.
Undergraduate & Postgraduate courses: IMED2002; IMED3003; IMED3004: PHAR2210; PHAR2220; PHAR3320; PHAR3320; PHAR1101
Roles and responsibilities
Clinical pharmacokinetics in the context of therapeutic drug monitoring; Pharmacology of macrophage regulation in inflammatory and neoplastic disease.
University of New South Wales
Award Date: 22 Feb 1988
The University of Western Australia
Award Date: 1 Dec 1975
Director, Clinical Pharmacology & Toxicology Laboratory15 Jul 2005 → …
Physician, Clinical Pharmacology & General Internal Medicine1 Jan 1987 → …
Research expertise keywords
- Clinical pharmacology
- Pharmacology of inflammatory cell differentiation and survival intracellular signalling